CMV in Hematopoietic Stem Cell Transplantation.
CMV in Hematopoietic Stem Cell Transplantation.
复制标题
DOI：
10.4084/mjhid.2016.031
复制
发表时间：
2016
影响因子：
3.2
通讯作者：
de la Cámara R
中科院分区：
文献类型：
--
作者：
de la Cámara R
由于其对干细胞移植（SCT）和实体器官移植患者（SOT）的结果的负面影响，CMV被称为“移植的巨魔”。SCT管理的最大进步之一是引入了先发制人的策略。自其引入以来，病毒血症的发生率如预期的那样保持不变，但早期CMV疾病的发生率显著下降。然而，尽管在预防CMV疾病方面取得了进展，但CMV今天仍然是发病率和死亡率的重要原因。晚期巨细胞病毒病仍然发生在相当大比例的患者中，所谓的巨细胞病毒间接效应正在导致显著的发病率和死亡率。幸运的是，在开发新的抗病毒药物、过继免疫疗法和DNA-CMV疫苗方面取得了一些进展，这些进展可能会在不久的将来改变CMV的管理。
Due to its negative impact on the outcome of stem cell transplant (SCT) and solid organ transplant patients (SOT) CMV has been called “the troll of transplantation”. One of the greatest advances in the management of SCT has been the introduction of the preemptive strategy. Since its introduction, the incidence of the viremia, as expected, remains unchanged but there has been a marked decline in the incidence of early CMV disease. However, in spite of the advances in prevention of CMV disease, CMV is still today an important cause of morbidity and mortality. Late CMV disease is still occurring in a significant proportion of patients and the so-called indirect effects of CMV are causing significant morbidity and mortality. Fortunately there have been several advances in the development of new antivirals, adoptive immunotherapy and DNA-CMV vaccines that might transform the management of CMV in the near future.